Navigation Links
Scientists develop method to determine order of mutations that lead to cancer
Date:6/30/2011

PORTLAND, Ore. -- Zeroing in on the early cell mutations that enable a cancer to grow is one of the best ways to find a personalized therapy to stop it. Scientists were able to use a statistical approach for the first time to map out the order in which these abnormalities form to analyze the pattern of DNA changes in advanced skin and ovarian tumors.

The study's findings, which are published in the July edition of Cancer Discovery, are the result of a collaboration of scientists at the Oregon Health & Science University Knight Cancer Institute; the Lawrence Berkeley National Laboratory, the University of California, San Francisco; and the Samsung Advanced Institute of Technology.

The researchers focused on assessing mutations involving TP53, a gene that normally prevents cells from becoming cancerous. By examining how additional copies of the mutant gene accumulated, they found that changes in TP53 occurred earlier in the disease's progression than previously believed.

Cancers are the result of multiple mutations, but the ones that happen first set the stage for additional abnormalities.

"We anticipate that this information will enhance our ability to detect cancer early when it is more likely to respond well to treatment," said Joe Gray, Ph.D., associate director for translational research for the OHSU Knight Cancer Institute.

Early mutations are also important because they are found in every cell of the cancer. "By understanding what happens early in a tumor's growth, you can develop therapies that will target all cancer cells," said Paul Spellman, Ph.D., of the Lawrence Berkeley National Laboratory and one of the lead scientists on the study. Spellman will join the OHSU Knight Cancer Institute in July.

Getting information about the order in which aberrations occur previously was difficult because it required the ability to analyze tumors as they developed. But, many cancers aren't detected until they've progressed beyond the initial growth phase. The researchers got around this problem by developing a novel statistical strategy. They integrated measurements of mutations with measurements of structural variations in a genome, which result in the cell having abnormal numbers of copies of one or more sections of DNA. "Now we have an ordering tool that should be broadly useful," Gray said.

So far, the researchers have investigated only a few types of cancer. Going forward, the analysis could be applied to all cancers. One near-term goal, Gray said, is to identify early mutations for which there are therapies already available.


'/>"/>

Contact: Elisa Williams
willieli@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related biology news :

1. USC scientists uncover mechanism by which chronic stress causes brain disease
2. UCLA stem cell scientists discover new airway stem cell
3. Johns Hopkins scientists expose cancer cells universal dark matter
4. Lithuanian scientists clean up at 2011 EUREKA Innovation Award
5. Scientists a step closer to understanding natural antifreeze molecules
6. Scientists uncover an unhealthy herds hypothesis
7. Qld fruit fly scientists in race against time
8. UC Riverside neuroscientists discovery could bring relief to epilepsy sufferers
9. Scientists breakthrough attracts new funding for high blood pressure research
10. Scientists develop a fatty kryptonite to defeat multidrug-resistant Super bugs
11. Scientists learn how horseweed shrugs off herbicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... Minn. , Dec. 7, 2016  Vyriad Inc. ... to the company,s Board of Directors. ... as we build our business and develop our oncolytic ... cancer therapy," said Stephen Russell , MD, PhD, ... Agnes , share our vision and passion for making ...
(Date:12/7/2016)... 7, 2016  Genprex, Inc. a biopharmaceutical company ... treatments, today announced that it has retained ICR ... strategic communications and advisory firm, to develop and ... will combine investor relations, public relations and digital ... profile of Genprex and its lead candidate Oncoprex, ...
(Date:12/7/2016)... , Dec. 7, 2016  Muse bio, a ... technologies, today announced that Dr. Kevin Ness ... the Board of Directors. Kevin succeeds ... becomes the company,s Chief Science Officer as well as ... Director of the BioDesign Center at the RAS Energy ...
(Date:12/7/2016)... NEW YORK and ANN ARBOR, ... a privately held biopharmaceutical company developing breakthrough immune modulatory ... clinical trial of the Company,s lead therapeutic candidate, LYC-30937- ... Psoriasis is often a debilitating skin disease that is ... the United States , with approximately ...
Breaking Biology Technology: